CIMIC – Trade Update

Posted on | by Leon Hinde

CIM:ASX is likely to see improved earnings in FY22 and we expect to soon see a recovery in the share price.

CIMIC is a high risk counter trend investment with the prospect of a multi-year recovery, once earnings hit an inflection point.

24/4 CIMIC breaks above the 10-day average after forming a new trend low mid-week at $16.86.


Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

TPG – 2020 Review

Posted on | by Leon Hinde

As the merger was effective for accounting purposes from 26 June 2020, TPG Telecom’s reported results for 2020 include a full twelve months of TPG Telecom Limited (formerly named VHA) and a contribution of six months and four days from TPG Corporation Limited (formerly named TPG Telecom).

Reported revenue for the year increased 24% from 2019 to $4.35 billion and reported EBITDA increased by 18% to $1.39 billion. We reported NPAT of $734 million, which includes a one-off, non-cash credit to income tax expense of $820 million.

In the first six months post-merger, the Group has generated $342 million
of net cash flow. The TPG Telecom Board resolved to pay a final dividend for 2020 of 7.5 cents per share.